John Maraganore steps into a new role at an upstart biotech as the godfather phase of his career takes shape
John Maraganore isn’t wasting any time shifting to a new post-Alnylam phase in his long biotech career. Startup wunderkind Beam Therapeutics has lured the soon-to-be ex-CEO to its board, where Maraganore can begin to play godfather to the next generation of biotechs looking to follow his footsteps from the lab to the marketplace.
In selecting the Beam offer — and it’s unlikely there will be any kind of shortage on that front — Maraganore will now play godfather to an upstart out of David Liu’s lab looking to do new things in gene editing. That fits snugly with Maraganore’s intention of stepping back from the day-to-day grind of the C-suite while advising startups on the long road ahead. And it’s a coup for Beam CEO John Evans, as every face on the board represents another opportunity to build credibility and attract new investors.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,400+ biopharma pros reading Endpoints daily — and it's free.